Urbina CV, Cantú VLG, Alcantar MDA, Martínez VA

Language: Spanish
References: 10
Page: 25-30
PDF size: 157.39 Kb.

ABSTRACT

Refractory thrombotic thrombocytopenic purpura is characterized by a persistent or passing decrease in platelet count, which increases the risk of bleeding depending on the degree of thrombocytopenia. This condition results from an imbalance between megakaryocyte platelet production and their accelerated destruction. Additionally, platelet production is affected by two main mechanisms: 1) intramedullary destruction of antibody-coated platelets by macrophages and 2) inhibition of megakaryopoiesis. The chronic form of the disease can be described as lasting longer than six months, and while spontaneous remissions may occur, they are infrequent. This manuscript reviews the risk factors, clinical manifestations, and available treatment options for managing a 42-year-old patient diagnosed with this condition.

REFERENCES

1. Orphanet. Púrpura trombótica trombocitopénica [Internet]. 2020 [citado 20 mayo 2024]. Disponible en: https://www.orpha.net/es/disease/detail/54057#menu.

2. Sánchez-Luceros A. Actualización en microangiopatíastrombóticas. Hematología. 2015;19:51-8. Disponible en:https://www.sah.org.ar/revistasah/numeros/10-vol%2019 extraordinario.pdf

3. Marcone MI, Colitto L, Ottobre M, Nosetti A, VivianaA. Utilidad de la medición de actividad de ADAMTS13 apropósito de un caso de púrpura trombocitopénica trombótica.Rev Bioquím Patol Clín (ByPC). 2023;87(3):45-51.Disponible en: https://www.revistabypc.org.ar/index.php/bypc/article/view/245

4. Gómez-Almaguer D, Tarín-Arzaga LC, Pérez JC. Púrpuratrombocitopénica trombótica y síndrome urémico hemolítico.En: Hematología. La sangre y sus enfermedades. 4ªed. McGraw-Hill Education; 2016. Disponible en: https://accessmedicina.mhmedical.com/content.aspx?bookid=1732§ionid=121016105

5. Lencinas G, Perés S, Aranda F, de Larrañaga G. ADAMTS-13: diagnóstico de laboratorio. Hematología.2020;24(1):95-100. Disponible en: https://revistahematologia.com.ar/index.php/Revista/article/view/256

6. Papakaonstantinou A, Kalmoukos P, Mpalaska A, KoravouEE, Gavriilaki E. ADAMTS 13 in the new era of TTP.Int J Mol Sci. 2024 Jul 26;25(15):80137. doi: 10.3390/ijms25158137

7. Zheng XL, Vesely SK, Cataland SR, Coppo P, Geldziler B,Iorio A, et al. ISTH guidelines for the diagnosis of thromboticthrombocytopenic purpura. J Thromb Haemost.2020;18(10):2486-95. doi: 10.1111/jth.15006

8. Mingot-Castellano ME, Pascual-Izquierdo C, GonzalezA, Viejo-Llorante A, Valcarcel-Ferreiras D, Sebastian E, etal. Recommendations for the diagnosis and treatment ofpatients with thrombotic thrombocytopenic purpura. MedClin (Barc). 2022;158(12):630.e1-630.e14. doi: 10.1016/j.medcli.2021.03.040

9. Dimopoulos K, Tripodi A, Goetze JP. Laboratory investigationand diagnosis of thrombotic thrombocytopenicpurpura. Crit Rev Clin Lab Sci. 2023;60(8):625-39. doi:

10. 10.1080/10408363.2023.223203910. Siniard RC, Gangaraju R, May JE, Marques MB. Challengesin the diagnosis of thrombotic thrombocytopenicpurpura. Expert Rev Hematol. 2023;16(11):861-73. doi:10.1080/10408363.2023.2232039